Last $7.17 USD
Change Today 0.00 / 0.00%
Volume 222.0K
STAA On Other Exchanges
As of 8:10 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

staar surgical co (STAA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/23/14 - $19.74
52 Week Low
01/20/15 - $6.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STAAR SURGICAL CO (STAA)

Related News

No related news articles were found.

staar surgical co (STAA) Related Businessweek News

No Related Businessweek News Found

staar surgical co (STAA) Details

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver lenses into the eye. The company offers implantable collamer lenses (ICL) comprising Visian ICL to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also provides intraocular lenses (IOL) that include aspheric IOLs that produce a clearer image than traditional spherical lenses; nanoFLEX IOL, a single piece collamer aspheric optic; Toric IOL for cataract patients to treat pre-existing astigmatism; and Preloaded Injector, a silicone or acrylic IOL preloaded into a single-use disposable injector. In addition, the company sells surgical products and other related instruments and devices; and manufactures AquaFlow device for the treatment of glaucoma. It markets its products to health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities. The company offers its products primarily under the STAAR, Visian, Collamer, CentraFlow, AquaPort, nanoFLEX, nanoPOINT, Epiphany, and AquaFlow names. It distributes its products through its sales representatives, independent sales representatives, and local distributors worldwide. STAAR Surgical Company was founded in 1982 and is headquartered in Monrovia, California.

335 Employees
Last Reported Date: 03/12/14
Founded in 1982

staar surgical co (STAA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $638.3K
Chief Financial Officer and Vice President
Total Annual Compensation: $122.0K
Vice President, Corporate Compliance Officer,...
Total Annual Compensation: $377.4K
Chief Accounting Officer and Vice President
Total Annual Compensation: $334.4K
Vice President of Global Research & Developme...
Total Annual Compensation: $366.7K
Compensation as of Fiscal Year 2013.

staar surgical co (STAA) Key Developments

STAAR Surgical Company Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:30 PM

STAAR Surgical Company Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 03:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

STAAR Surgical Company Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 03:30 PM

STAAR Surgical Company Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 03:30 PM. Venue: The Westin Grand Central, New York, New York, United States.

STAAR Surgical Company Gains Final Step in Regulatory Approval for Visian(R) ICL(TM) with CentraFLOW(R) in China

STAAR Surgical Company announced that it has received the Approval Certification from CFDA to market its Visian ICL with CentraFLOW(R) technology in China effective November 3, 2014. The Visian ICL with CentraFLOW uses a proprietary port in the center of the ICL optic, KS-AquaPORT(R), intended to optimize the flow of fluid within the eye without affecting the quality of vision. The CentraFLOW technology eliminates the need for surgeons to perform a YAG peripheral iridotomy procedure days before the ICL implant, simplifying the procedure and increasing patient comfort while providing the superior visual outcomes of the ICL. STAAR Surgical personnel in China began marketing the new technology. To date over 400 surgeons have been trained on the Visian ICL technology and additional surgeon training is already underway. The first orders for the Visian ICL with CentraFLOW were placed and leading ophthalmologists who were trained during the recent ESCRS meeting will begin utilizing the new technology. There will be a CentraFLOW training course in China for surgeons in November followed by two additional training courses before year end. Distributors in China were trained at a recent meeting in September and additional training will take place in November.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STAA:US $7.17 USD 0.00

STAA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.35 USD +0.02
Biolase Inc $2.63 USD +0.05
Cutera Inc $12.99 USD +0.14
Iridex Corp $8.98 USD +0.06
SurModics Inc $22.06 USD -0.21
View Industry Companies

Industry Analysis


Industry Average

Valuation STAA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STAAR SURGICAL CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at